- RecruitingPhase I and Phase II (Integrated)- Other
A Master Protocol Phase I/II Study to Investigate Biomarker‑Guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy for the Treatment of Participants with Advanced/Recurrent Ovarian Cancer (Ovarian Platform)
This study is testing a new drug called Saruparib for women with advanced or recurrent ovarian cancer. Researchers want to see how safe the drug is and if it can shrink tumors or control cancer growth. It's an early-stage study, combining two phases to learn about the drug's effects.
For: Advanced/Recurrent Ovarian cancerItaly · Spain - RecruitingTherapeutic exploratory (Phase II)
SARUPANC - A multicentric, single arm, phase II trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
This study is testing a new drug called Saruparib for people with a specific type of advanced pancreatic cancer. It's looking at how well the drug shrinks tumours after 16 weeks and will also check side effects and quality of life.
For: Pancreatic (PAAD)France - RecruitingPHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
This study is looking at a new drug, Saruparib, for men with high-risk prostate cancer and a faulty BRCA gene. It aims to see if adding Saruparib to standard treatments can help prevent the cancer from spreading.
For: Prostate CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
This study is testing a new cancer medicine, AZD5335, on its own and with other treatments for various solid tumors. Researchers want to see if it's safe, tolerable, and if it can shrink tumors or stop them from growing. It's for people with advanced cancer.
For: Ovarian Cancer · Lung Adenocarcinoma · Endometrial CancerUnited States · Australia · Canada - RecruitingPHASE3
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
This study is for men with prostate cancer that has spread and is still responding to hormone treatment, after recent docetaxel or Lu-PSMA therapy. It tests a new drug called saruparib combined with standard hormone treatment, to see if it works better than standard treatment alone.
For: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)United States · Austria · Brazil - RecruitingPHASE1, PHASE2
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
This study is testing a new medicine, AZD4956, alone or with another medicine, Saruparib, for people with advanced solid tumours. It aims to see if they are safe and how well they work, especially for tumours with certain genetic changes.
For: Solid TumoursUnited States · Australia · Japan - Active not recruitingPHASE3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
This study is testing a new drug, Saruparib, for men with advanced prostate cancer that is still responding to hormone treatment. It aims to see if adding Saruparib to standard hormone therapy works better than standard therapy alone to slow down cancer growth.
For: Metastatic Castration-Sensitive Prostate CancerUnited States · Australia · Austria